Abstract
Influenza A viruses (IAV) are likely candidates for pandemics. This report summarizes the results of the Swiss national program for surveillance of influenza viruses in pigs and transmissions to humans between 2010 and 2022. Challenges and optimization options in the program are discussed.
Nasal swabs or lung tissue samples from pigs with influenza-like signs (e.g. fever, cough) were screened by real-time RT-PCR for swine influenza virus (SIV) genomes, including that of the 2009 pandemic strain A(H1N1)pdm09; positive samples were subtyped for H1, N1, H3 and N2 by RT-PCR and Sanger sequencing. In parallel, humans with influenza-like symptoms and recent contact with diseased pigs were asked to self-sample themselves with a nasal swab. Human swabs were tested for IAV, and positive swabs further subtyped to identify potential cross-species transmission between swine and humans.
In the pigs, SIV was detected in 375 of 674 farm visits. H1N1 is the only subtype detected in Swiss pigs so far. The (H1N1)pdm09 strain (HA clade 1A) was only detected in seven out of 375 SIV positive farm visits. Phylogenetic analyses from partial hemagglutinin (HA) and neuraminidase (NA) genome sequences indicate that the remaining pigs were infected with the Eurasian avian lineage (HA clade 1C), which is predominant in swine in Europe. The Swiss H1N1 strains form distinct clusters within HA clades 1C.2.1 and 1C.2.2 and seem to evolve comparably slowly. Infection of humans with SIV was identified in five cases. Sequence analysis assigned the five viruses to the Eurasian avian lineage (C), clades 1C.2.1 and 1C.2.2. There was no evidence for sustained human-to-human transmission.
Although no critical IAV variants seem to have emerged so far in Switzerland, further surveillance of influenza viruses at the swine-human interface is of major importance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The national monitoring program for SIV is funded by the Swiss Federal Food Safety and Veterinary Office (FSVO) and the Federal Office of Public Health (FOPH).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The human samples from the target population (persons with influenza-like symptoms and recent contact with diseased pigs) were obtained by self-sampling. Based on an official letter from the Federal Office of Public Health (FOPH) stating that human data and samples were collected in accordance with the Swiss Epidemics Act (EpG SR 818.101), the cantonal ethics committee of Zurich waived ethical approval for this work (BASEC Req-2024-01630).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.